mhurhangee/ep-ind-claims huggingface dataset:
A composition, comprising: (a) at least one fatty acid sugar ester; (b) at least one anionic surfactant selected from amino acid surfactants and taurate surfactants; (c) at least one polyoxyalkylenated polyol fatty acid ester having an HLB value of from 6 to 12; (d) at least one oil; (e) at least one polyol; and (f) water wherein the (a) fatty acid sugar ester is selected from the group consisting of sucrose laurate, sucrose myristate, sucrose palmitate, sucrose stearate, and mixtures thereof, and the (c) polyoxyalkylenated polyol fatty acid ester having an HLB value of from 6 to 12 is selected from POE glyceryl fatty acid esters. (a) at least one fatty acid sugar ester; (b) at least one anionic surfactant selected from amino acid surfactants and taurate surfactants; (c) at least one polyoxyalkylenated polyol fatty acid ester having an HLB value of from 6 to 12; (d) at least one oil; (e) at least one polyol; and (f) water wherein the (a) fatty acid sugar ester is selected from the group consisting of sucrose laurate, sucrose myristate, sucrose palmitate, sucrose stearate, and mixtures thereof, and the (c) polyoxyalkylenated polyol fatty acid ester having an HLB value of from 6 to 12 is selected from POE glyceryl fatty acid esters.
An orthopaedic implant, comprising: a patella component, comprising: a solid-metal base comprising (i) a posterior base surface, and (ii) an anterior base surface having a number of pegs extending outwardly therefrom, a porous-metal coating disposed on the anterior base surface and the pegs, and the polymer bearing having a posterior bearing surface configured to articulate with a pair of femoral condyles of a femoral component, characterized in that: the posterior base surface has a number of pockets formed therein with each of the pockets having an undercut formed therein; the polymer bearing is molded to the posterior base surface of the solid-metal base. a patella component, comprising: a solid-metal base comprising (i) a posterior base surface, and (ii) an anterior base surface having a number of pegs extending outwardly therefrom, a porous-metal coating disposed on the anterior base surface and the pegs, and a solid-metal base comprising (i) a posterior base surface, and (ii) an anterior base surface having a number of pegs extending outwardly therefrom, a porous-metal coating disposed on the anterior base surface and the pegs, and the polymer bearing having a posterior bearing surface configured to articulate with a pair of femoral condyles of a femoral component, characterized in that: the posterior base surface has a number of pockets formed therein with each of the pockets having an undercut formed therein; the polymer bearing is molded to the posterior base surface of the solid-metal base. the posterior base surface has a number of pockets formed therein with each of the pockets having an undercut formed therein; the polymer bearing is molded to the posterior base surface of the solid-metal base.
A fuel cell comprising: a membrane electrode assembly having a polymer electrolyte membrane and catalyst layers (34, 36) disposed therein; an anode separator disposed on an anode side of the membrane electrode assembly; a cathode separator disposed on a cathode side of the membrane electrode assembly; a plurality of first ribs (50, 50A) disposed in parallel with each other in a gas passage space between the membrane electrode assembly and the anode separator; a plurality of second ribs (55, 55A) disposed in parallel with each other in a gas passage space between the membrane electrode assembly and the cathode separator; and a support (60, 65, 65A) made of a metal porous base material and disposed between the membrane electrode assembly and at least either of the first ribs (50, 50A) and the second ribs (55, 55A), wherein contact surfaces of the first ribs (50, 50A) in contact with the membrane electrode assembly or the support (60, 65, 65A) and contact surfaces of the second ribs (55, 55A) in contact with the membrane electrode assembly or the support (60, 65, 65A) are offset from each other in a cross sectional view in the direction orthogonal to a gas passage direction and positioned without overlapping with each other in a projection in a stacking direction. a membrane electrode assembly having a polymer electrolyte membrane and catalyst layers (34, 36) disposed therein; an anode separator disposed on an anode side of the membrane electrode assembly; a cathode separator disposed on a cathode side of the membrane electrode assembly; a plurality of first ribs (50, 50A) disposed in parallel with each other in a gas passage space between the membrane electrode assembly and the anode separator; a plurality of second ribs (55, 55A) disposed in parallel with each other in a gas passage space between the membrane electrode assembly and the cathode separator; and a support (60, 65, 65A) made of a metal porous base material and disposed between the membrane electrode assembly and at least either of the first ribs (50, 50A) and the second ribs (55, 55A), wherein contact surfaces of the first ribs (50, 50A) in contact with the membrane electrode assembly or the support (60, 65, 65A) and contact surfaces of the second ribs (55, 55A) in contact with the membrane electrode assembly or the support (60, 65, 65A) are offset from each other in a cross sectional view in the direction orthogonal to a gas passage direction and positioned without overlapping with each other in a projection in a stacking direction.
A method of determining a glycemic state in a subject, the method comprising: chemically oxidizing a saliva sample from the subject, thereby oxidizing one or more glycoproteins in the saliva sample to generate one or more oxidation products, wherein the one or more glycoproteins comprise sialic acid and fucose, and wherein the one or more oxidation products comprise one or more aldehydes; and quantifying the one or more aldehydes in the oxidized saliva sample, wherein a significant elevation in a quantity of the one or more aldehydes relative to an established normal reference range indicates that the subject has diabetes or pre-diabetes. chemically oxidizing a saliva sample from the subject, thereby oxidizing one or more glycoproteins in the saliva sample to generate one or more oxidation products, wherein the one or more glycoproteins comprise sialic acid and fucose, and wherein the one or more oxidation products comprise one or more aldehydes; and quantifying the one or more aldehydes in the oxidized saliva sample, wherein a significant elevation in a quantity of the one or more aldehydes relative to an established normal reference range indicates that the subject has diabetes or pre-diabetes.
A vehicle control device configured to start a predetermined drive assist if it is determined that there is a risk of collision between a self vehicle and an object around the self vehicle, characterized in that the vehicle control device is configured to determine a commencing time of the predetermined drive assist according to a value calculated by a first formula including an inter-vehicular distance between the self vehicle and the object, a velocity (Vm) of the self vehicle, a relative velocity (Vr) of the object to the self vehicle, and an acceleration (Ap) of the object as variables, if it has been determined that the self vehicle is accelerating, and the vehicle control device is configured to determine a commencing time of the predetermined drive assist according to a value calculated by a second formula including the inter-vehicular distance between the self vehicle and the object, the velocity (Vm) of the self vehicle, and the relative velocity (Vr) of the object to the self vehicle as variables, and including a relative acceleration (Ar) of the object to the self vehicle as a variable instead of the acceleration (Ap) of the object in the first formula, if it has been determined that the self vehicle is decelerating, the first formula is CV = α × Vm − β × Vr − γ × Ap / f D, the second formula is CV = α × Vm − β × Vr − γ × Ar / f D, α, β and γ are positive constants, and f is a function of the inter-vehicular distance, where the value of f increases with the increase in the inter-vehicular distance D. characterized in that the vehicle control device is configured to determine a commencing time of the predetermined drive assist according to a value calculated by a first formula including an inter-vehicular distance between the self vehicle and the object, a velocity (Vm) of the self vehicle, a relative velocity (Vr) of the object to the self vehicle, and an acceleration (Ap) of the object as variables, if it has been determined that the self vehicle is accelerating, and the vehicle control device is configured to determine a commencing time of the predetermined drive assist according to a value calculated by a second formula including the inter-vehicular distance between the self vehicle and the object, the velocity (Vm) of the self vehicle, and the relative velocity (Vr) of the object to the self vehicle as variables, and including a relative acceleration (Ar) of the object to the self vehicle as a variable instead of the acceleration (Ap) of the object in the first formula, if it has been determined that the self vehicle is decelerating, the first formula is CV = α × Vm − β × Vr − γ × Ap / f D, the second formula is CV = α × Vm − β × Vr − γ × Ar / f D, α, β and γ are positive constants, and f is a function of the inter-vehicular distance, where the value of f increases with the increase in the inter-vehicular distance D. α, β and γ are positive constants, and f is a function of the inter-vehicular distance, where the value of f increases with the increase in the inter-vehicular distance D.
Adjustment mechanism for a motor vehicle lock arrangement, the adjustment mechanism having an adjustment element and a drive train, the adjustment element being adjustable between a forward end position and a rearward end position in a movement cycle with a forward movement generated by way of actuation of the drive train and an opposed, spring-driven rearward movement, the rearward end position being assigned a rearward end stop, against which an engagement element of the adjustment element impinges in the case of the rearward movement, and/or the forward end position being assigned a forward end stop, against which an engagement element of the adjustment element impinges in the case of the forward movement, characterized in that the respective end stop (15, 17) and/or the engagement element has a gaiter-like buffer element which compresses axially when the engagement element impinges on this end stop (15, 17).
A preassembled bearing unit which is designed for attachment on a shaft of a pump assembly, with a sleeve for receiving the shaft and with a bearing sleeve which is fixed on the sleeve at the outer periphery, wherein the sleeve at a first axial end comprises a first contact shoulder, wherein the sleeve comprises a second contact shoulder at a second opposite axial end, said second contact shoulder fixing the bearing sleeve in an axial direction, wherein the bearing sleeve bears with an axial end on the first contact shoulder and with the opposite second axial end supports itself on the second contact shoulder, so that the bearing sleeve is fixed in the axial direction between the contact shoulders (9, 10), characterised in that the sleeve forms an engagement element, designed for the positive, rotationally fixed engagement with the shaft or with a component which is connected to the shaft, wherein the engagement element is designed as a formed part of sheet metal and has an essentially pot-like shape with an axial surface or a base which faces the sleeve and forms the first contact shoulder.
A three-dimensional display system, comprising: a display device being divided into a display region and a non-display region in a display plane of the display device, the display region being located at the middle of the display device, the non-display region being located at the periphery of the display device, the non-display region encompassing the display region; a barrier located at a light emergent side of the display device; and a distance adjusting structure arranged between the display device and the barrier, the distance adjusting structure being configured to adjust a viewing distance of the three-dimensional display system by adjusting a distance between the display device and the barrier, characterized in that the distance adjusting structure comprises a hollow cavity arranged at the non-display region, the hollow cavity is a loop cavity encompassing the display region, and the hollow cavity is configured such that a volume of the hollow cavity is increased or decreased accordingly by inputting or outputing gas or liquid to/from the hollow cavity. a display device being divided into a display region and a non-display region in a display plane of the display device, the display region being located at the middle of the display device, the non-display region being located at the periphery of the display device, the non-display region encompassing the display region; a barrier located at a light emergent side of the display device; and a distance adjusting structure arranged between the display device and the barrier, the distance adjusting structure being configured to adjust a viewing distance of the three-dimensional display system by adjusting a distance between the display device and the barrier, characterized in that the distance adjusting structure comprises a hollow cavity arranged at the non-display region, the hollow cavity is a loop cavity encompassing the display region, and the hollow cavity is configured such that a volume of the hollow cavity is increased or decreased accordingly by inputting or outputing gas or liquid to/from the hollow cavity.
A method for determining the presence or absence of Herpes Simplex Virus 1 (HSV-1) in a sample, said method comprising: contacting a sample, said sample suspected of containing HSV-1, with at least two oligomers for amplifying a target region of an HSV-1 target nucleic acid, wherein the at least two amplification oligomers comprise (a) a first amplification oligomer comprising a first target-hybridizing sequence that is from about 15 to about 27 contiguous nucleotides contained in the sequence of SEQ ID NO:31 and that includes at least the sequence of SEQ ID NO:30; and (b) a second amplification oligomer comprising a second target-hybridizing sequence that is from about 15 to about 27 contiguous nucleotides contained in the sequence of SEQ ID NO:33 and that includes at least the sequence of SEQ ID NO:32; performing an in vitro transcription mediated nucleic acid amplification reaction, wherein any HSV-1 target nucleic acid present in said sample is used as a template for generating an amplification product; and detecting the presence or absence of the amplification product, thereby indicating the presence or absence of HSV-1 in said sample. contacting a sample, said sample suspected of containing HSV-1, with at least two oligomers for amplifying a target region of an HSV-1 target nucleic acid, wherein the at least two amplification oligomers comprise (a) a first amplification oligomer comprising a first target-hybridizing sequence that is from about 15 to about 27 contiguous nucleotides contained in the sequence of SEQ ID NO:31 and that includes at least the sequence of SEQ ID NO:30; and (b) a second amplification oligomer comprising a second target-hybridizing sequence that is from about 15 to about 27 contiguous nucleotides contained in the sequence of SEQ ID NO:33 and that includes at least the sequence of SEQ ID NO:32; (a) a first amplification oligomer comprising a first target-hybridizing sequence that is from about 15 to about 27 contiguous nucleotides contained in the sequence of SEQ ID NO:31 and that includes at least the sequence of SEQ ID NO:30; and (b) a second amplification oligomer comprising a second target-hybridizing sequence that is from about 15 to about 27 contiguous nucleotides contained in the sequence of SEQ ID NO:33 and that includes at least the sequence of SEQ ID NO:32; performing an in vitro transcription mediated nucleic acid amplification reaction, wherein any HSV-1 target nucleic acid present in said sample is used as a template for generating an amplification product; and detecting the presence or absence of the amplification product, thereby indicating the presence or absence of HSV-1 in said sample.
A recombinant avian infectious coryza vaccine comprising as an active ingredient a peptide consisting of a sequence comprising the amino acid sequence shown by SEQ ID NO: 35, said sequence being within the amino acid sequence shown by SEQ ID NO: 1 with addition of 1 to 200 amino acid residues at the N-terminal and/or C-terminal thereof.
A polyester elastomer resin composition comprising: a polyester elastomer; an aliphatic amide compound; and a copolyether, wherein the polyester elastomer comprises a hard segment and a soft segment, the hard segment comprising a polyester that comprises, as constituents, an aromatic dicarboxylic acid and an aliphatic and/or alicyclic diol, the soft segment being at least one member selected from aliphatic polyethers, aliphatic polyesters, and aliphatic polycarbonates, the copolyether comprises two or more different types of alkylene units and has a number average molecular weight of 1500 to 5000, wherein the number average molecular weight is determined by dissolving the copolyether in deuterated chloroform (CDCl 3)/trifluoroacetic acid at a volume ratio of 85/15, and calculating the number average molecular weight from the spectral ratio of ethylene oxide and propylene oxide, and the amount of the terminal group obtained by 1 H-NMR, and the aliphatic amide compound is present in an amount of 0.01 to 1 part by mass, and the copolyether is present in an amount of 0.1 to 10 parts by mass, per 100 parts by mass of the polyester elastomer. a polyester elastomer; an aliphatic amide compound; and a copolyether, wherein the polyester elastomer comprises a hard segment and a soft segment, the hard segment comprising a polyester that comprises, as constituents, an aromatic dicarboxylic acid and an aliphatic and/or alicyclic diol, the soft segment being at least one member selected from aliphatic polyethers, aliphatic polyesters, and aliphatic polycarbonates, the copolyether comprises two or more different types of alkylene units and has a number average molecular weight of 1500 to 5000, wherein the number average molecular weight is determined by dissolving the copolyether in deuterated chloroform (CDCl 3)/trifluoroacetic acid at a volume ratio of 85/15, and calculating the number average molecular weight from the spectral ratio of ethylene oxide and propylene oxide, and the amount of the terminal group obtained by 1 H-NMR, and the aliphatic amide compound is present in an amount of 0.01 to 1 part by mass, and the copolyether is present in an amount of 0.1 to 10 parts by mass, per 100 parts by mass of the polyester elastomer.
An injection system, comprising a carrier, an actuator and at least one medicament cartridge, the carrier comprising: - a first slot for at least partially containing the actuator; - a second slot for at least partially containing the medicament cartridge; - and a user interface adapted to provide at least one of a visual signal and an audible signal; the medicament cartridge comprising: - a housing having open proximal and distal ends, the housing being adapted to hold a syringe; - a first coupling mechanism; and - a syringe including a needle, the syringe being axially translatable relative to the housing between a retracted position in which the needle is covered by the housing and an extended position in which the needle is exposed; the actuator comprising: - a plunger - a motor adapted to translate the plunger; - a control button adapted to actuate the motor wherein the medicament cartridge is removable from the carrier, the injection system being characterized in that; the actuator further comprises a second coupling mechanism adapted to detachably engage the first coupling mechanism; and wherein the actuator is removable from the carrier and when the actuator and cartridge are removed from the carrier, are adapted to be coupled to each other to form a delivery device. - a first slot for at least partially containing the actuator; - a second slot for at least partially containing the medicament cartridge; - and a user interface adapted to provide at least one of a visual signal and an audible signal; - a housing having open proximal and distal ends, the housing being adapted to hold a syringe; - a first coupling mechanism; and - a syringe including a needle, the syringe being axially translatable relative to the housing between a retracted position in which the needle is covered by the housing and an extended position in which the needle is exposed; - a plunger - a motor adapted to translate the plunger; - a control button adapted to actuate the motor
Apparatus for odorising a packaging, such as for example a food-preserving tray, in which a product, more particularly a food product, is packaged and provided, wherein the apparatus is suitable for producing and dispensing an odorising/aromatising substance (G1+G2+L, OD) in gaseous form in the packaging containing the product, before the packaging is hermetically sealed, comprising: - a mixing system for producing a gas mixture (G1+G2); - an oiler or nebuliser for nebulising an odorising/aromatising liquid and mixing it with the gas mixture (G1+G2) produced and fed by the mixing system; and - a tank, where the mixture (G1+G2+L) of nebulised liquid and gas is stored and the molecular exchange takes place between this gas mixture, supplied by the mixing system and the nebulised liquid, so as to obtain the odorising/aromatising substance to be used for odorising the packaging; characterised in that said apparatus, including the respective mixing system, comprises only mechanical parts and pneumatic devices (20, 30, 40), in turn including pneumatic lines, valves of various type, and similar devices, for producing, controlling and dispensing the odorising/aromatising substance in the packaging to be odorised, and therefore does not comprise electric and/or electronic devices which could be the source of risks for safety in the environment wherein the odorising apparatus is installed. - a mixing system for producing a gas mixture (G1+G2); - an oiler or nebuliser for nebulising an odorising/aromatising liquid and mixing it with the gas mixture (G1+G2) produced and fed by the mixing system; and - a tank, where the mixture (G1+G2+L) of nebulised liquid and gas is stored and the molecular exchange takes place between this gas mixture, supplied by the mixing system and the nebulised liquid, so as to obtain the odorising/aromatising substance to be used for odorising the packaging;